title: Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
abstract: BACKGROUND
  Whether ileal absorption of bile acid is up or downregulated in chronic cholestasis is still debated, and most evidence has come from animal studies.
  
  
  OBJECTIVE
  To compare ileal bile acid absorption in patients with primary biliary cirrhosis (PBC) and in healthy control subjects, and to assess the effect of ursodeoxycholic acid (UDCA).
  
  
  METHODS
  We studied 14 PBC patients before and during (n=11) UDCA administration, 14 healthy control subjects, and 14 Crohn's disease patients (as disease controls).
  
  
  METHODS
  We used cholescintigraphy to measure retention in the enterohepatic circulation over five successive days of the bile acid analogue (75)Se-homocholic acid-taurine ((75)SeHCAT) as an index of ileal bile acid absorption. Results were expressed as (75)SeHCAT fractional turnover rate (FTR) and t(1/2)12.
  
  
  RESULTS
  (75)SeHCAT FTR was 0.19 (0.11)/day, 0.34 (0.11)/day (p<0.001), and 0.83 (0.32)/day in PBC patients, healthy controls (p<0.0001), and Crohn's patients (p<0.001), respectively, which increased to 0.36 (0.16)/day in PBC patients during UDCA treatment (p<0.005). (75)SeHCAT t(1/2)12 was 4.8 (2.1) days in PBC patients, 2.2 (0.5) days (p<0.001) in healthy controls, and 1.0 (0.5) days (p<0.001) in Crohn's disease patients. (75)SeHCAT t(1/2)12 decreased to 2.2 (0.93) days (p< 0.001) in PBC patients during UDCA treatment.
  
  
  CONCLUSIONS
  Our results support the concept that ileal bile acid absorption is upregulated in PBC patients, and that this effect may contribute towards damaging the cholestatic liver. This upregulation of bile acid absorption is abolished by UDCA.
authors.affiliation: Nuclear Medicine, Spedali Civili and University of Brescia, Italy. lanzini@med.unibs.it
authors.forename: A
authors.initials: A
authors.lastname: Lanzini
authors.forename: M G
authors.initials: MG
authors.lastname: De Tavonatti
authors.forename: B
authors.initials: B
authors.lastname: Panarotto
authors.forename: S
authors.initials: S
authors.lastname: Scalia
authors.forename: A
authors.initials: A
authors.lastname: Mora
authors.forename: F
authors.initials: F
authors.lastname: Benini
authors.forename: O
authors.initials: O
authors.lastname: Baisini
authors.forename: F
authors.initials: F
authors.lastname: Lanzarotto
mesh_terms: D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000378:metabolism*; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007082:Ileum / Q000378:metabolism*; D007408:Intestinal Absorption / Q000187:drug effects*; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy / Q000378:metabolism*; D008875:Middle Aged; D012644:Selenium Radioisotopes / Q000378:metabolism; D013654:Taurine / Q000378:metabolism; D013656:Taurocholic Acid / Q000031:analogs & derivatives* / Q000378:metabolism*; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage*
chemical_list: D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D012644:Selenium Radioisotopes; D013654:Taurine; D013656:Taurocholic Acid; D014580:Ursodeoxycholic Acid; C033638:23-seleno-25-homotaurocholic acid